Calling the results “a potential new standard-of-care” for pediatric brain tumors, Novartis said its chemotherapy combination of Tafinlar (dabrafenib) and Mekinist (trametinib) reduced the risk of disease progression or death in an ongoing study by 69 percent at 12 months, compared to standard chemotherapy.
Source: Drug Industry Daily